Dr Lal PathLabs Sets Ambitious Growth Targets, Plans Expansion Across India
Dr Lal PathLabs announces plans to achieve a 27% margin by FY26, with expansion plans including 15-20 new laboratories focusing on southern and western India. The company reported impressive Q4 results with revenue up 10.50%, EBITDA up 17%, and net profit surging 81.20% year-over-year. The board recommended a final dividend of Rs 6.00 per share for FY25.
25Apr 25
Dr. Lal PathLabs Q4 Profit Soars 83%, Surpasses Expectations
Dr. Lal PathLabs Limited posted strong Q4 FY25 results with net profit up 83% YoY to Rs 154.80 crore, outpacing revenue growth of 10.5% to Rs 602.60 crore. EBITDA grew 17% to Rs 169.00 crore with improved margin of 28%. For FY25, revenue increased 10.50% to Rs 24,614.00 crore, while net profit rose 35.90% to Rs 4,922.00 crore. The company announced a final dividend of Rs 6.00 per share, bringing the total FY25 dividend to Rs 24.00 per share.
15Apr 25
Dr. Lal PathLabs Pioneers Advanced Amyloidosis Test in South Asia
Dr. Lal PathLabs has become the first diagnostic chain in South Asia to launch an advanced test for amyloidosis, a group of rare diseases characterized by abnormal protein buildup in organs. This breakthrough enhances early detection and management capabilities for these complex disorders. The introduction of this test demonstrates Dr. Lal PathLabs' commitment to innovation and could strengthen its market position in the diagnostic industry.
07Apr 25
Dr. Lal Path Labs Witnesses Significant Block Trade on NSE
A significant block trade of 101,444 shares of Dr. Lal Path Labs Ltd. occurred on the National Stock Exchange. The shares were traded at Rs. 2,448.00 each, totaling Rs. 24.83 crore. While the identities of the buyer and seller remain undisclosed, such large transactions often indicate strategic moves by institutional investors or major shareholders.
02Apr 25
Dr. Lal PathLabs Witnesses Substantial Block Trade on NSE
A significant block trade of Dr. Lal PathLabs Ltd. shares occurred on the National Stock Exchange (NSE). The transaction involved 593,348 shares at ₹2,406.50 per share, totaling ₹142.79 crore. This large-scale trade could potentially impact the company's short-term trading patterns and may indicate shifts in ownership or strategy among major investors.
05Mar 25
Dr. Lal PathLabs Sees Major Block Trade Worth ₹54.54 Crore on NSE
A significant block trade of approximately 227,175 shares of Dr. Lal PathLabs Ltd. occurred on the National Stock Exchange. The shares were traded at ₹2,400.75 each, totaling a transaction value of ₹54.54 crore. This large-scale trade has drawn market attention, potentially signaling shifts in institutional or large investor holdings.
27Feb 25
Dr. Lal Path Labs Witnesses Significant Block Trade on NSE
A significant block trade of 116,643 shares of Dr. Lal Path Labs Ltd. occurred on the NSE, valued at Rs. 27.26 crores. The average price per share was Rs. 2,336.95. This large transaction could potentially impact the stock's trading pattern in the short term.